Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling Source: Annual Congress 2009 - New bronchodilators Year: 2009
Single inhaler therapy with budesonide/formoterol in an allergic rat model: a new therapeutic strategy in asthma Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Budesonide and formoterol in a single inhaler is safe and effective in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Use of inhalation corticosteroids (ICS) in children with asthma in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 395s Year: 2002
Combined inhaled corticosteroid and long acting β agonist treatment of paediatric asthma: experience of an asthma care programme Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018
Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective? Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Is the combination of long-acting β2 -agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids}, Source: Eur Respir J 2012; 40: 570-579 Year: 2012
A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016
Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
The development of an algorithm for the rational use of intravenous salbutamol in severe paediatric asthma Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents Source: Eur Respir J 2003; 22: Suppl. 45, 445s Year: 2003